Glycopyrronium Shortage Update: What Patients Need to Know in 2026

If you've been searching "glycopyrronium shortage" or had trouble getting your prescription filled, you're likely wondering: Is there an official shortage right now, or is this just my local pharmacy? Here's what patients need to know about glycopyrronium availability in 2026.

Is Glycopyrronium in an Active Shortage in 2026?

As of 2026, generic glycopyrrolate oral tablets are not on the FDA's active drug shortage list and are generally available at pharmacies nationwide. However, glycopyrrolate injectable solution has experienced repeated supply disruptions over the past several years and may be on shortage at certain times — hospital pharmacists manage this routinely. If you take the oral tablet, Qbrexza topical cloth, Cuvposa oral solution, or an inhalation form, your situation depends on the specific product.

Here's a formulation-by-formulation status breakdown:

Generic oral tablets (1 mg, 2 mg): Generally available. Multiple manufacturers supply the market. Minor pharmacy-level stock gaps are possible but not a systemic national shortage.

Injectable glycopyrrolate (0.2 mg/mL): Historically prone to supply disruptions. Hospital pharmacies manage this with substitution protocols. Check ASHP.org for current status.

Qbrexza topical cloth (2.4%): Not typically classified as a shortage item, but limited specialty pharmacy distribution and insurance barriers make it difficult to access for many patients.

Cuvposa oral solution: Limited manufacturers and specialty nature means some pharmacy-level stock gaps occur periodically. Generally orderable by pharmacies within 1–3 business days.

COPD inhalation products: Seebri Neohaler and Lonhala Magnair are generally available. Bevespi Aerosphere (glycopyrrolate + formoterol) may require pharmacy ordering at smaller locations.

Why Has Glycopyrrolate Injectable Been in Shortage?

Injectable glycopyrrolate has appeared on ASHP and FDA shortage lists multiple times. The primary reasons mirror the broader pattern of sterile injectable drug shortages:

Few manufacturers: Only a small number of pharmaceutical-grade sterile fill facilities make injectable glycopyrrolate. When one has a manufacturing or quality issue, national supply can drop quickly.

Manufacturing complexity: Sterile injectables require specialized facilities with rigorous cleanroom standards. A single FDA warning letter or quality finding can halt production for months.

Low profit margins: Generic injectable drugs are often inexpensive commodity products with thin margins, making it economically unattractive for new manufacturers to enter the market.

History of Glycopyrrolate Shortages

Glycopyrrolate injectable has been documented on the ASHP drug shortage list at various points over the past decade, typically due to manufacturing issues at one of the few U.S. manufacturers or raw material supply chain disruptions. These shortages primarily affect hospital anesthesia departments and ICU/palliative care settings where the injectable form is used. Retail pharmacy patients taking the oral formulation are rarely directly impacted by these hospital-side shortages.

What Patients Should Do Right Now

If you're having trouble filling a glycopyrronium prescription in 2026, take these steps:

Don't assume a nationwide shortage. In most cases for oral tablets, your local pharmacy is simply out of stock and another pharmacy nearby will have it.

Search nearby pharmacies. Use medfinder to have pharmacies near you checked for your specific medication, formulation, and quantity.

Check the official shortage database. The FDA drug shortage database (accessdata.fda.gov) and ASHP.org list current, active shortages. If glycopyrrolate isn't listed, it's not in a declared national shortage.

Contact your prescriber early. If you're running low, reach out to your provider at least a week before you run out so there's time to locate a pharmacy or discuss alternatives.

Consider mail-order. Mail-order pharmacies often maintain more consistent inventory for generic maintenance medications like glycopyrrolate oral tablets.

What If You're on Cuvposa or Qbrexza and Supply Is Disrupted?

For specialty formulations, talk to your prescriber about whether an alternative medication or formulation is appropriate while supply is being sorted out. Our post on alternatives to glycopyrronium covers options by indication.

Key Takeaways

Generic glycopyrrolate oral tablets are generally available in 2026 and not in national shortage.

Injectable glycopyrrolate has a history of supply disruptions; hospital pharmacists manage this with substitution protocols.

Specialty products like Qbrexza face access barriers from insurance and distribution requirements, not necessarily supply shortages.

When in doubt, check multiple pharmacies — medfinder can do this search for you automatically.